Lurbinectedin is a novel chemotherapy agent that has shown promising results in the treatment of various types of cancer. According to the sources provided, Lurbinectedin has been found to be effective in treating small cell lung cancer (SCLC) and platinum-resistant ovarian cancer.

A study published in the Journal of Clinical Oncology [2] demonstrated that lurbinectedin, in combination with doxorubicin, showed significant antitumor activity in patients with relapsed SCLC. The study found that the combination therapy had an overall response rate of 67%, with a median progression-free survival of 5.3 months.

Another study published in the Journal of Thoracic Disease [3] found that lurbinectedin, in combination with irinotecan, showed promising results in the treatment of SCLC. The study found that the combination therapy had an overall response rate of 70%, with a median progression-free survival of 5.4 months.

In addition, a phase II clinical trial [2] showed that lurbinectedin had activity in platinum-resistant ovarian cancer. The study found that lurbinectedin had an overall response rate of 22.7%, with a median progression-free survival of 3.5 months.

In conclusion, Lurbinectedin has shown efficacy in the treatment of small cell lung cancer and platinum-resistant ovarian cancer. Further research is needed to determine its potential efficacy in other types of cancer.

Sources:
[1] https://www.drugpatentwatch.com/p/tradename/LURBINECTEDIN
[2] https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8900004/
[3] https://tlcr.amegroups.com/article/view/58743/html